Omniscient Neurotechnology vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Omniscient Neurotechnology (o8t) is the pioneer of clinical connectomics with its FDA-cleared Quicktome brain mapping platform; raised up to $36M Series D led by NRFC ($20M); partnered with Jacobs Institute in 2025.
About
Omniscient Neurotechnology (branded as o8t) is an Australian medical technology company founded in 2019 and headquartered in Sydney. Omniscient is the global pioneer of clinical connectomics — the application of brain network science to patient care. Its flagship product, Quicktome, is the world''s first FDA-cleared medical device to generate detailed maps of brain networks from standard MRI scans using artificial intelligence and machine learning. Neurosurgeons use Quicktome before life-changing brain surgeries to visualize critical functional networks (motor, language, vision, memory) and plan surgical approaches that minimize neurological damage.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Omniscient Neurotechnology vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.